Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study

Although immune-checkpoint inhibitors (ICIs) have become an important choice of treatment for advanced NSCLC, recent reports show hyperprogressive disease (HPD) after ICI administration. The clinico-pathological features of HPD still remain unclear. Here we report a 65-year-old man with lung adenoca...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Respir Med Case Rep
Main Authors: Tanaka, Yuko, Matsubara, Osamu, Asada, Kazuhiro, Muramatsu, Aya, Suzuki, Makoto, Shirai, Toshihiro
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2019
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6586950/
https://ncbi.nlm.nih.gov/pubmed/31249779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2019.100885
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares